Tvardi Therapeutics, Inc.
TVRD
Last
$1.03
Day
-4.6%
1y
-97.5%
5y
-94.1%
52w
-97.5%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
2026-11-1233d
EMA 21
1.34
EMA 50
1.69
EMA 200
4.56
20d high
-46.0%
5y high
-97.5%
5y range
0th
Positions held
Your positionsTVRD isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
-24
Hold
avoid
Signal
Strong Sell
Target
$1.36
Stop
$0.85
Stop distance
17.5%
Target vs last
+32.0%
Fundamentals
| Market cap | $14.41M | Enterprise value | -$1.21M | Trailing P/E | — | Forward P/E | -0.48 |
| PEG | — | Price / book | 0.70 | Beta | — | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -126.2% | ROA | -55.5% | Debt / equity | 0.02 |
| Current ratio | 1.87 | Free cash flow | -$16.26M | Analyst recommendation | buy | Mean target | $9.25 |
| 52w high | $43.65 | 52w low | $0.93 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$6.5M | -$6.8M | -$7.3M | -$5.5M | $4.2M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | $2.6M |
| Operating income | -$6.6M | -$7.1M | -$7.6M | -$5.9M | -$8.9M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — |
| Net income | -$18.2M | -$29.4M | -$17.3M | -$20.5M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$26.7M | -$28.1M | -$18.7M | -$21.2M |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-24 · New Preclinical Data Further Support Potential for Tvardi’s STAT3 Inhibitors in Ulcerative Colitis (UC)
2026-08-26 · Tvardi Therapeutics to Participate in Upcoming Investor Events
2026-08-14 · Tvardi: Q2 Earnings Snapshot
2026-08-14 · Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update
2026-07-30 · Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109
Price (daily)
Full chart · RSI · MACD · patternsTVRD · daily-31.2% over 13 sessions
Close EMA21 EMA50 EMA200
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin